mature dendritic cells vaccine

DRUG2 trials

Sponsors

Heinrich-Heine-Universitaet Duesseldorf

Conditions

Recurrent Glioblastomanewly diagnosed glioblastoma

Phase 1

Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity

WithdrawnCTIS2026-525397-19-00

Heinrich-Heine-Universitaet DuesseldorfRecurrent Glioblastoma

Target: 6Updated: 2026-08-20

Phase 2

Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma

Active, not recruitingCTIS2024-514820-18-00

Heinrich-Heine-Universitaet Duesseldorfnewly diagnosed glioblastoma

Start: 2018-03-07Target: 136Updated: 2025-10-10